Score	Observations	Animal ID
1	<13% of BVs with astrocyte accumulation and <16% associated with microglia. <21% of tissue with hypertrophic microglia, <22% of tissue with hypertrophic astrocytes. Maximum nodule size <5000 μm^2 .	AGM12
2	<13% of BVs with astrocyte accumulation and <16% associated with microglia. <21% of tissue with hypertrophic microglia, <22% of tissue with hypertrophic astrocytes. Maximum nodule size ≥5000µm².	AGM14, AGM8, AGM6
3	<13% of BVs with astrocyte accumulation and <16% associated with microglia. 21-26% of tissue with hypertrophic microglia, <22% of tissue with hypertrophic astrocytes. Maximum nodule size ≥5000μm².	AGM10
4	>13% of BVs with astrocyte accumulation and >16% associated with microglia. >21% of tissue with hypertrophic microglia, <22% of tissue with hypertrophic astrocytes. Maximum nodule size ≥5000µm².	AGM11, AGM9, AGM5
5	>13% of BVs with astrocyte accumulation and >16% associated with microglia. >21% of tissue with hypertrophic microglia, >22% of tissue with hypertrophic astrocytes. Maximum nodule size ≥5000µm².	AGM7, AGM13, AGM15, AGM16

Supplementary Table 2. Subjective neuroinflammation scoring. Iba1, GFAP, and HLA-DR IHC observations were used to assign a composite neuroinflammation score to each animal. Values were used to investigate correlations between neuroinflammation and behavioral assessments. <u>Abbreviations</u>: **BV** – blood vessel